Genfit S.A.
GNFT
Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosā¦ read more
Healthcare
Biotechnology
6 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$3.89
Price-1.77%
-$0.07
1Y
Price
Market Cap
$193.709m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-301.6%
EBITDA Margin-358.7%
Net Profit Margin+332.3%
Free Cash Flow MarginRevenue
$94.878m
+232.2%
1y CAGR+66.3%
3y CAGR+2641.3%
5y CAGREarnings
-$19.347m
+33.0%
1y CAGR-41.3%
3y CAGR+10.6%
5y CAGREPS
-$0.50
+13.8%
1y CAGR-48.9%
3y CAGR+0.0%
5y CAGRBook Value
$69.224m
$151.424m
Assets$82.200m
Liabilities$62.133m
DebtDebt to Assets
41.0%
-5.5x
Debt to EBITDAFree Cash Flow
-$43.853m
+24.3%
1y CAGR-42.8%
3y CAGR+18.4%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in EUR.No items found.
Press Releases
Statements and updates from the company